Numbers for newly diagnosed malignant melanoma are mounting, with the highest prevalence in Caucasians [1]. In males, this type of cancer has currently the fastest increasing incidence rate in the United Kingdom. Worldwide, malignant melanoma is most common in New Zealand and Australia.
âIn this study, we have reviewed new malignant melanoma diagnoses to see which ones are more likely to metastasise in terms of location,â said lead investigator Dr Mohammed Al Abadie (Cross Hospital; Cannock Chase Hospital, United Kingdom). A total of 45 patients were included in the study. The diagnosis of malignant melanoma had been established through biopsies. According to tumour location, 37 patients were assigned to a group with melanomas below the neck while 8 had above neck malignant melanomas. CT-scans were used for staging, and sentinel lymph node biopsies were offered to all patients with stages 2 or higher. In the group of below neck tumours, no distant metastases were identified and only 1 patient (2.7%) had a positive biopsy of the sentinel lymph node. Lymph node melanoma was found in both patients that agreed to sentinel lymph node biopsy in the above neck group. These 2 patients also had distant metastases.
- Al Abadie, et al. P0672, EADV 2019, 9-13 Oct, Madrid, Spain.
Posted on
Previous Article
« The Rosacea Tracker may aid clinical decision-making Next Article
PURE study: risk factors cardiovascular disease in low- and high-income countries »
« The Rosacea Tracker may aid clinical decision-making Next Article
PURE study: risk factors cardiovascular disease in low- and high-income countries »
Table of Contents: EADV 2019
Featured articles
Late-Breaking News
IL-17A blocker effective in paediatric psoriasis patients
Rituximab beats mycophenolate mofetil in pemphigus vulgaris
Acne highly influenced by climate, pollutants, and unhealthy diet
JAK inhibition plus TCS lead to high clearance rates in AD
No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD
Green light for a second JAK inhibitor in AD
Topical ruxolitinib effective in vitiligo
Emerging Therapies
Small molecules: interesting novel treatment options in AD
IL-1âș blockade: a new treatment option in AD
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents
How to manage conjunctivitis in AD patients treated with a biologic
Biologics: increasingly used in paediatric dermatology
Spotlight on Psoriasis
IL-17 blocker: effective and safe in patients with comorbidities
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker
Relationship psoriasis and NAFLD: new data on the hepato-dermal axis
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints
No hint of teratogenicity through ixekizumab
New Insights in Photoprotection
Systemic photoprotection: a valuable addition to topical sun protection
The underestimated effect of visible light
Urticaria
Comorbidities more common in chronic urticaria, psoriasis, and AD
D-Dimer as future biomarker in CSU management?
Ligelizumab for CSU: symptom control and high response rates in re-treatment
Rosacea â From New Spectrum to New Therapy
New guidance on rosacea therapy according to phenotype
Best of the Posters
Above-the-neck melanoma more prone to metastases
Reduced sleep quality in dermatoses influenced by itch and pain
Anxiety and depression are common in families of AD infants
Certolizumab pegol efficacious for head and neck psoriasis
Related Articles
December 9, 2019
IL-17A blocker effective in paediatric psoriasis patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com